JP2010500003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500003A5 JP2010500003A5 JP2009504513A JP2009504513A JP2010500003A5 JP 2010500003 A5 JP2010500003 A5 JP 2010500003A5 JP 2009504513 A JP2009504513 A JP 2009504513A JP 2009504513 A JP2009504513 A JP 2009504513A JP 2010500003 A5 JP2010500003 A5 JP 2010500003A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acid
- acid sequence
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 483
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 466
- 229920001184 polypeptide Polymers 0.000 claims description 465
- 150000001413 amino acids Chemical class 0.000 claims description 237
- 108091033319 polynucleotide Proteins 0.000 claims description 136
- 239000002157 polynucleotide Substances 0.000 claims description 136
- 102000040430 polynucleotide Human genes 0.000 claims description 136
- 230000026731 phosphorylation Effects 0.000 claims description 133
- 238000006366 phosphorylation reaction Methods 0.000 claims description 133
- 238000000034 method Methods 0.000 claims description 108
- 230000004071 biological effect Effects 0.000 claims description 93
- 239000003795 chemical substances by application Substances 0.000 claims description 92
- 239000002773 nucleotide Substances 0.000 claims description 85
- 125000003729 nucleotide group Chemical group 0.000 claims description 85
- 150000001875 compounds Chemical class 0.000 claims description 67
- 206010006187 Breast cancer Diseases 0.000 claims description 64
- 208000026310 Breast neoplasm Diseases 0.000 claims description 64
- 239000000758 substrate Substances 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 238000012216 screening Methods 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 29
- 101001129654 Homo sapiens Prohibitin-2 Proteins 0.000 claims description 28
- 102100031156 Prohibitin-2 Human genes 0.000 claims description 28
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 claims description 27
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 claims description 27
- 108091028664 Ribonucleotide Proteins 0.000 claims description 24
- 239000002336 ribonucleotide Substances 0.000 claims description 24
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 24
- 230000000692 anti-sense effect Effects 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 108091081021 Sense strand Proteins 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 21
- 108020004459 Small interfering RNA Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000004055 small Interfering RNA Substances 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 13
- 108010033040 Histones Proteins 0.000 claims description 12
- 230000006907 apoptotic process Effects 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 102000020233 phosphotransferase Human genes 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 101150034941 AURKB gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 45
- 102000006947 Histones Human genes 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 42
- 102100032306 Aurora kinase B Human genes 0.000 description 23
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 23
- 108700008625 Reporter Genes Proteins 0.000 description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 8
- 239000004473 Threonine Substances 0.000 description 8
- 230000008827 biological function Effects 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102100033636 Histone H3.2 Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 4
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 4
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 108010011110 polyarginine Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- UKVZSPHYQJNTOU-GQJPYGCMSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-GQJPYGCMSA-N 0.000 description 2
- 108010062307 AAVALLPAVLLALLAP Proteins 0.000 description 2
- 101800002011 Amphipathic peptide Proteins 0.000 description 2
- 102000008178 Cyclin B1 Human genes 0.000 description 2
- 108010060385 Cyclin B1 Proteins 0.000 description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- 108010061875 HN-1 peptide Proteins 0.000 description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
- 108010088535 Pep-1 peptide Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 2
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 108010025307 buforin II Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 2
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 229950006344 nocodazole Drugs 0.000 description 2
- 108010043655 penetratin Proteins 0.000 description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 108010062760 transportan Proteins 0.000 description 2
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83742806P | 2006-08-10 | 2006-08-10 | |
| US60/837,428 | 2006-08-10 | ||
| US84025006P | 2006-08-25 | 2006-08-25 | |
| US60/840,250 | 2006-08-25 | ||
| US91502207P | 2007-04-30 | 2007-04-30 | |
| US60/915,022 | 2007-04-30 | ||
| PCT/JP2007/065992 WO2008018642A2 (en) | 2006-08-10 | 2007-08-10 | Genes and polypeptides relating to breast cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500003A JP2010500003A (ja) | 2010-01-07 |
| JP2010500003A5 true JP2010500003A5 (cg-RX-API-DMAC7.html) | 2010-09-24 |
| JP5339291B2 JP5339291B2 (ja) | 2013-11-13 |
Family
ID=38627000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504513A Expired - Fee Related JP5339291B2 (ja) | 2006-08-10 | 2007-08-10 | 乳癌に関連する遺伝子およびポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8673548B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2057187B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5339291B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090064378A (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0716498A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2660438A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG174071A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008018642A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200512298A (en) | 2003-09-24 | 2005-04-01 | Oncotherapy Science Inc | Method of diagnosing breast cancer |
| UA97787C2 (ru) | 2005-07-29 | 2012-03-26 | Таргитед Гроут, Инк. | Защита доминантным негативным мутантным krp-белком ингибирования активного циклин-cdk-комплекса krp-белком дикого типа |
| JP5514453B2 (ja) * | 2008-03-04 | 2014-06-04 | 株式会社キノファーマ | 発光タンパク質を用いたリン酸化酵素阻害物質のスクリーニング方法 |
| EP2275567A1 (en) * | 2009-07-15 | 2011-01-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nucleic acid expression construct and its use as a cell proliferation marker |
| AU2011223883B2 (en) * | 2010-03-01 | 2015-10-08 | Cavion, Inc. | Cancer diagnosis and imaging |
| EP2638167A4 (en) * | 2010-11-12 | 2014-03-26 | Targeted Growth Inc | DOMINANT NEGATIVE MUTANT KIP PROTEINS IN ZEA-MAIZE AND METHOD FOR THEIR USE |
| EP2697378A4 (en) | 2011-04-11 | 2014-10-01 | Targeted Growth Inc | IDENTIFICATION AND USE OF KRP MUTANTS IN PLANTS |
| WO2012142116A2 (en) | 2011-04-11 | 2012-10-18 | Targeted Growth, Inc. | Identification and use of krp mutants in wheat |
| US9725490B2 (en) | 2011-07-29 | 2017-08-08 | Tokushima University | ERAP1-derived peptide and use thereof |
| ES2665576T3 (es) * | 2011-10-28 | 2018-04-26 | Oncotherapy Science, Inc. | Péptidos TOPK y vacunas que los incluyen |
| CA3106312C (en) * | 2011-12-16 | 2025-09-23 | National University Corporation Tokyo Medical And Dental University | CHIMERIC DOUBLE-STRANDED NUCLEIC ACID |
| GB201121924D0 (en) * | 2011-12-20 | 2012-02-01 | Fahy Gurteen Labs Ltd | Detection of breast cancer |
| WO2016011143A1 (en) * | 2014-07-15 | 2016-01-21 | Temple University Of The Commonwealth System Of Higher Education | Stabilized peptide fragments from redoxin proteins as cancer biomarkers |
| CN104497147B (zh) * | 2014-12-23 | 2018-07-03 | 四川大学 | 一种双受体识别的串联型穿膜肽修饰的肿瘤靶向纳米递药系统 |
| JP6923135B2 (ja) | 2016-01-19 | 2021-08-18 | 国立大学法人徳島大学 | がん治療用ペプチド及びそれを含む医薬組成物 |
| US20210206818A1 (en) | 2016-01-22 | 2021-07-08 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| EP3656783A4 (en) | 2017-07-19 | 2021-04-07 | Tokushima University | PEPTIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION WITH IT |
| CN114773480A (zh) * | 2022-06-07 | 2022-07-22 | 厦门大学附属翔安医院 | 一种抗topk第32位丝氨酸残基磷酸化的抗体 |
| CN116082447A (zh) * | 2022-09-09 | 2023-05-09 | 湖南大学 | 一种多肽及其制备方法 |
| CN117757789A (zh) * | 2022-09-26 | 2024-03-26 | 领星生物科技（上海）有限公司 | 用于抑制肿瘤生长的siRNA及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656698B1 (en) * | 1999-06-30 | 2003-12-02 | Millennium Pharmaceuticals, Inc. | 12832, a novel human kinase-like molecule and uses thereof |
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001296448A1 (en) | 2000-10-03 | 2002-04-15 | Curagen Corporation | Tumor marker and methods of use |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| CA2429343A1 (en) * | 2000-11-17 | 2002-08-01 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002059271A2 (en) | 2001-01-25 | 2002-08-01 | Gene Logic, Inc. | Gene expression profiles in breast tissue |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU2002357726A1 (en) | 2001-11-15 | 2003-06-10 | The Regents Of The University Of California | Compositions and methods for the suppression of mammary epithelial cell proliferation |
| US6833247B2 (en) | 2002-05-14 | 2004-12-21 | Origene Technologies, Inc. | Regulated prostate cancer genes |
| WO2003064599A2 (en) | 2002-01-25 | 2003-08-07 | Origene Technologies, Inc | Cancer genes |
| US20030235533A1 (en) | 2002-02-19 | 2003-12-25 | Idec Pharmaceuticals Corporation | Prostate specific genes and the use thereof in design or therapeutics |
| AU2003259913A1 (en) * | 2002-08-19 | 2004-03-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20060194199A1 (en) | 2002-09-30 | 2006-08-31 | Oncotherapy Science, Inc. | Method for diagnosing testicular seminomas |
| US6971476B2 (en) * | 2003-09-05 | 2005-12-06 | D B Industries, Inc. | Safety harness |
| TW200512298A (en) | 2003-09-24 | 2005-04-01 | Oncotherapy Science Inc | Method of diagnosing breast cancer |
| WO2006085684A2 (en) | 2005-02-10 | 2006-08-17 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| EP1907582B1 (en) | 2005-07-27 | 2012-01-04 | Oncotherapy Science, Inc. | Ect2 as a therapeutic target for esophageal cancer |
| EP1907580A2 (en) | 2005-07-28 | 2008-04-09 | Oncotherapy Science, Inc. | Method for diagnosing and treating renal cell carcinoma |
| RS53552B1 (sr) | 2007-10-11 | 2015-02-27 | Astrazeneca Ab | Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b |
| KR20110079847A (ko) | 2008-10-30 | 2011-07-08 | 온코세라피 사이언스 가부시키가이샤 | 7-하이드록시-벤조이미다졸-4-일-메타논 유도체 및 이를 함유하는 ｐｂｋ 저해제 |
-
2007
- 2007-08-10 CA CA002660438A patent/CA2660438A1/en not_active Abandoned
- 2007-08-10 JP JP2009504513A patent/JP5339291B2/ja not_active Expired - Fee Related
- 2007-08-10 WO PCT/JP2007/065992 patent/WO2008018642A2/en not_active Ceased
- 2007-08-10 SG SG2011057932A patent/SG174071A1/en unknown
- 2007-08-10 US US12/377,024 patent/US8673548B2/en not_active Expired - Fee Related
- 2007-08-10 EP EP07805938.3A patent/EP2057187B1/en not_active Not-in-force
- 2007-08-10 KR KR1020097004837A patent/KR20090064378A/ko not_active Withdrawn
- 2007-08-10 BR BRPI0716498-0A2A patent/BRPI0716498A2/pt not_active IP Right Cessation
-
2014
- 2014-01-23 US US14/162,487 patent/US9187557B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500003A5 (cg-RX-API-DMAC7.html) | ||
| Lu et al. | A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway | |
| JP4060886B2 (ja) | Ｓｈ３結合ペプチドの単離および利用 | |
| KR101653774B1 (ko) | 올리고펩타이드 화합물 및 이의 용도 | |
| Takagi et al. | Ki67 antigen contributes to the timely accumulation of protein phosphatase 1γ on anaphase chromosomes | |
| He et al. | S100A11: diverse function and pathology corresponding to different target proteins | |
| JP6014904B2 (ja) | Ｅｒａｐ１由来ペプチド及びその使用 | |
| RU2010111120A (ru) | Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого | |
| Jeong et al. | Role of annexin A5 in cisplatin-induced toxicity in renal cells: molecular mechanism of apoptosis | |
| WO1999058675A2 (en) | Human genes and gene expression products v | |
| Liu et al. | FANCD2 and RAD51 recombinase directly inhibit DNA2 nuclease at stalled replication forks and FANCD2 acts as a novel RAD51 mediator in strand exchange to promote genome stability | |
| JP2010512730A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Identification of phosphorylation consensus sequences and endogenous neuronal substrates of the psychiatric risk kinase TNIK | |
| JP2010512730A (ja) | 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ | |
| Chen et al. | Direct interaction of 14-3-3ζ with ezrin promotes cell migration by regulating the formation of membrane ruffle | |
| Hemming et al. | Disease‐associated missense variants in ZBTB18 disrupt DNA binding and impair the development of neurons within the embryonic cerebral cortex | |
| Moreno et al. | Distinctive interactomes of RNA polymerase II phosphorylation during different stages of transcription | |
| Qu et al. | The nuclear localization of SET mediated by impα3/impβ attenuates its cytosolic toxicity in neurons | |
| JP2010523081A5 (cg-RX-API-DMAC7.html) | ||
| CN108289924A (zh) | 阻断组蛋白识别结构域的小分子 | |
| US8604163B2 (en) | EEF2K assays for identifying compounds that inhibit EEF2K activity | |
| Reimer et al. | Phosphorylation of the N-terminal domain regulates subcellular localization and DNA binding properties of the peptidyl-prolyl cis/trans isomerase hPar14 | |
| Mandel-Gutfreund et al. | ARTS, the unusual septin: structural and functional aspects | |
| Evans et al. | Analysis of the Fragile X mental retardation protein isoforms 1, 2 and 3 interactions with the G-quadruplex forming semaphorin 3F mRNA | |
| WO2006015084A2 (en) | Compositions, kits and assays containing reagents directed to cortactin and an arg/abl protein kinase |